Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial (Q46854681)
Jump to navigation
Jump to search
scientific article published on 16 January 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial |
scientific article published on 16 January 2017 |
Statements
1 reference
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial (English)
1 reference
Christopher Sorli
1 reference
Shin-Ichi Harashima
1 reference
George M Tsoukas
1 reference
Jeffrey Unger
1 reference
Julie Derving Karsbøl
1 reference
Thomas Hansen
1 reference
Stephen C Bain
1 reference
16 January 2017
1 reference
5
1 reference
251-260
1 reference
4
1 reference
Identifiers
1 reference
1 reference